[Mechanisms of nutrient and drug transfer through the blood-brain barrier and their pharmacological changes].
The blood-brain barrier is formed by the endothelial cells of the brain capillaries. Its primary characteristic is the impermeability of the capillary wall due to the presence of complex tight junctions and a low endocytic activity. Essential nutrients are delivered to the brain by selective transport mechanisms, such as glucose transporter and a variety of amino acid transporters. Although most drugs enter the brain by passive diffusion through the endothelial cells depending of their lipophilicity, degree of ionization, molecular weight, relative brain tissue and plasma bindings--some of them can use specific endogenous transporters. In these cases, binding competition on the transporter with endogenous products or nutrients can occur and limit the drug transfer. The blood-brain barrier can be a major impediment for the treatment of diseases of the central nervous system, since many drugs are unable to reach this organ at therapeutic concentrations. Various attempts have been made to overcome the limiting access of drugs to the brain: chemical modification of drugs, development of more hydrophobic analogs or linking an active compound to a specific carrier. Transient opening of the blood-brain barrier has been achieved by intracarotid infusion of hypertonic mannitol solutions or of bradykinin analogs in humans. Another way to increase or decrease brain delivery of drugs is to modulate the P-glycoprotein (P-gp) whose substrates are actively pumped out the cell into the capillary lumen. We actually dispose of many P-gp inhibitors or inducers in order to enhance the therapeutic effects of centrally acting drugs or to decrease central adverse effects of peripheric drugs.
Jolliet-Riant
P
P
Service de Pharmacologie, Faculté de Médecine de Créteil, Paris XII, Créteil.
Tillement
J P
JP
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism*; D000596:Amino Acids / Q000493:pharmacokinetics*; D001665:Binding Sites / Q000187:drug effects; D001812:Blood-Brain Barrier / Q000187:drug effects* / Q000502:physiology*; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D001921:Brain / Q000378:metabolism*; D002199:Capillary Permeability / Q000187:drug effects / Q000502:physiology; D004234:Diuretics, Osmotic / Q000493:pharmacokinetics*; D005947:Glucose / Q000493:pharmacokinetics*; D006801:Humans; D008353:Mannitol / Q000493:pharmacokinetics*; D014815:Vitamins / Q000493:pharmacokinetics*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000596:Amino Acids; D004234:Diuretics, Osmotic; D014815:Vitamins; D008353:Mannitol; D005947:Glucose; D001920:Bradykinin
Mécanismes de transfert à travers la barrière hémato-encéphalique des nutriments et des médicaments et leurs modifications pharmacologiques.